ArticleApplied immunohistochemistry & molecular morphology : AIMM2014
Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.
Article in Applied immunohistochemistry & molecular morphology : AIMM, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Oncogenic Fusions HarboringCancers · 2025Review
- Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection.Laryngoscope investigative otolaryngology · 2024Article
- Comparative Analysis of Gene Expression Analysis Methods for RNA in Situ Hybridization Images.The Journal of molecular diagnostics : JMD · 2024Article
- Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.Molecular cancer research : MCR · 2023Article
- The evolving landscape of prostate cancer somatic mutations.The Prostate · 2022Review
- QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- DNA Methylation Profiling for Diagnosing Undifferentiated Sarcoma with Capicua Transcriptional Receptor (International journal of molecular sciences · 2020Review
- Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.Virchows Archiv : an international journal of pathology · 2019Article
- The Genomics of Prostate Cancer: A Historic Perspective.Cold Spring Harbor perspectives in medicine · 2019Review
- RNAscopeOncotarget · 2017Article
- Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.The Journal of molecular diagnostics : JMD · 2017Article
- Article
- Article
- Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.European urology · 2015Article
- Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.The Prostate · 2015Article
- Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.Hormones & cancer · 2015Article
- Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The genetic basis of 50% to 60% of prostate cancer (PCa) is attributable to rearrangements in E26 transformation-specific (ETS) (ERG, ETV1, ETV4, and ETV5), BRAF, and RAF1 genes and overexpression of SPINK1. The development and validation of reliable detection methods are warranted to classify various molecular subtypes of PCa for diagnostic and prognostic purposes. ETS gene rearrangements are typically detected by fluorescence in situ hybridization and reverse-transcription polymerase chain reaction methods. Recently, monoclonal antibodies against ERG have been developed that detect the truncated ERG protein in immunohistochemical assays where staining levels are strongly correlated with ERG rearrangement status by fluorescence in situ hybridization. However, specific antibodies for ETV1, ETV4, and ETV5 are unavailable, challenging their clinical use. We developed a novel RNA in situ hybridization-based assay for the in situ detection of ETV1, ETV4, and ETV5 in formalin-fixed paraffin-embedded tissues from prostate needle biopsies, prostatectomy, and metastatic PCa specimens using RNA probes. Further, with combined RNA in situ hybridization and immunohistochemistry we identified a rare subset of PCa with dual ETS gene rearrangements in collisions of independent tumor foci. The high specificity and sensitivity of RNA in situ hybridization provides an alternate method enabling bright-field in situ detection of ETS gene aberrations in routine clinically available PCa specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.